Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients

Neurological Sciences

Volumn 31, Issue 5, 2010, Pages 565-569

  Nevrly, Martin ^a   Kanovsky, Petr ^a   Vranova, Hana ^a   Langova, Katerina ^a   Hlustik, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Entacapone; Homocysteine; Parkinson's disease

Indexed keywords

ENTACAPONE; HOMOCYSTEINE; LEVODOPA;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; TREATMENT DURATION;

AGED; ANTIPARKINSON AGENTS; CATECHOLS; FEMALE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; TIME FACTORS;

EID: 78049364432     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-010-0262-0     Document Type: Article

References (37)

1. MS Morris 2003 Homocysteine and Alzheimer's disease Lancet Neurol 2 425 428 1:CAS:528:DC%2BD3sXms1yhsbw%3D 10.1016/S1474-4422(03)00438-1 12849121 (Pubitemid 36793935)
2. MS Morris PF Jacques IH Rosenberg, et al. 2000 Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III J Nutr 130 3073 3076 1:CAS:528: DC%2BD3cXptVKmu7o%3D 11110872
3. IJ Perry H Refsum RW Morris SB Ebrahim PM Ueland AG Shaper 1995 Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men Lancet 346 1395 1398 1:CAS:528:DyaK28XlvFCqtw%3D%3D 10.1016/S0140-6736(95)92407-8 7475822
4. GN Welch J Loscalzo 1998 Homocysteine and atherothrombosis N Engl J Med 338 1042 1050 1:CAS:528:DyaK1cXislaqtr4%3D 10.1056/NEJM199804093381507 9535670 (Pubitemid 28180407)
5. S Seshadri A Beiser J Selhub, et al. 2002 Plasma homocysteine as a risk factor for dementia and Alzheimer's disease N Engl J Med 346 476 483 1:CAS:528:DC%2BD38XhtFCktrw%3D 10.1056/NEJMoa011613 11844848 (Pubitemid 34441738)
6. KA Jellinger 2003 Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study Acta Neuropathol (Berl) 105 415 419
7. D Kubová I Rektor 2001 Vaskulární parkinsonský syndrom-historie a současnost Čes a Slov Neurol Neurochir 64 /97 75 81
8. G Levy MX Tang ED Louis, et al. 2002 The association of incident dementia with mortality in PD Neurology 59 1708 1713 1:STN:280:DC%2BD38jhs1yjtA%3D%3D 12473757
9. I Rektorová 2004 Účinek donepezilu na demenci u Parkinsonovy nemoci a Alzheimerovy nemoci. Pilotní studie Čes a Slov Neurol Neurochir 67 /100 359 363
10. P Valkovič P Blažíček J Benetin P Kukumberg 2006 Homocysteín, levodopa a Parkinsonova choroba Čes a Slov Neurol Neurochir 69/102 3 183 188
11. F Blandini R Fancellu E Martignoni, et al. 2001 Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease Clin Chem 47 1102 1104 1:CAS:528:DC%2BD3MXktFels70%3D 11375298
12. JW Miller J Selhub MR Nadeau CA Thomas RG Feldman PA Wolf 2003 Effect of l-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status Neurology 60 1125 1129 1:STN:280:DC%2BD3s7msFShsw%3D%3D 12682318
13. T Müller B Werne B Fowler W Kuhn 1999 Nigral endothelial dysfunction, homocysteine, and Parkinson's disease Lancet 354 126 127 10.1016/S0140-6736(99)01660-8 10408491 (Pubitemid 29313150)
14. F Ozer H Meral L Hanoglu, et al. 2006 Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations Neurol Res 28 8 853 858 1:CAS:528:DC%2BD2sXks1Krsw%3D%3D 10.1179/016164106X110445 17288745 (Pubitemid 44904462)
15. JD Rogers A Sanchez-Saffon AB Frol R Diaz-Arrastia 2003 Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease Arch Neurol 60 59 64 10.1001/archneur.60.1.59 12533089
16. P Valkovič J Benetin P Blažíček Ľ Valkovičová K Gmitterová P Kukumberg 2005 Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients Parkinsonism Relat Disord 11 253 256 10.1016/j.parkreldis.2005.01.007 15878587 (Pubitemid 40692838)
17. K Yasui K Nakaso H Kowa T Takeshima K Nakashima 2003 Levodopa-induced hyperhomocysteinaemia in Parkinson's disease Acta Neurol Scand 108 66 67 1:STN:280:DC%2BD3s3otVentA%3D%3D 10.1034/j.1600-0404.2003.00135.x 12807397 (Pubitemid 36791996)
18. S Zoccolella P Lamberti E Armenise, et al. 2005 Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications Parkinsonism Relat Disord 11 131 133 1:STN:280:DC%2BD2M7gsV2iug%3D%3D 10.1016/j.parkreldis. 2004.07.008 15734674 (Pubitemid 40279156)
19. JL Ostrem GA Kang I Subramanian, et al. 2005 The effect of entacapone on homocysteine levels in Parkinson disease Neurology 64 8 1482 1:STN:280:DC%2BD2M3hslCisA%3D%3D 15851757
20. JD Finkelstein 1998 The metabolism of homocysteine: pathways and regulation Eur J Pediatr 157 Suppl 2 S40 S44 1:CAS:528:DyaK1cXivVeksbg%3D 10.1007/PL00014300 9587024
21. J Selhub 1999 Homocysteine metabolism Annu Rev Nutr 19 217 246 1:CAS:528:DyaK1MXlt1ejsLw%3D 10.1146/annurev.nutr.19.1.217 10448523 (Pubitemid 29380603)
22. American Society of Human Genetics/American College of Medical Genetics Test, Transfer Committee Working Group 2008 Measurement and use of total plasma homocysteine Am J Hum Genet 63 1541 1543
23. JJ Genest Jr JR McNamara B Upson, et al. 1991 Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease Arterioscler Thromb 11 1129 1136 1911700
24. WG Haynes 2002 Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins Cardiovasc Drugs Ther 16 391 399 1:CAS:528:DC%2BD3sXntFSjsw%3D%3D 10.1023/A:1022130217463 12652108 (Pubitemid 36255739)
25. J Selhub PF Jacques AG Bostom, et al. 1995 Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis N Engl J Med 332 286 291 1:STN:280:DyaK2M7hsFOitw%3D%3D 10.1056/NEJM199502023320502 7816063
26. O Stanger W Herrmann K Pietrzik, et al. 2003 DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations Clin Chem Lab Med 41 1392 1403 1:CAS:528:DC%2BD3sXpsV2hs7c%3D 10.1515/CCLM.2003.214 14656016 (Pubitemid 37493551)
27. MP Mattson TB Shea 2003 Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders Trends Neurosci 26 137 146 1:CAS:528:DC%2BD3sXht1Ghsrk%3D 10.1016/S0166-2236(03)00032-8 12591216 (Pubitemid 36183675)
28. P Allain BA Le E Cordillet QL Le H Bagheri JL Montastruc 1995 Sulfate and cysteine levels in the plasma of patients with Parkinson's disease Neurotoxicology 16 527 529 1:STN:280:DyaK287kslWguw%3D%3D 8584284
29. W Kuhn R Roebroek H Blom, et al. 1998 Elevated plasma levels of homocysteine in Parkinson's disease Eur Neurol 40 225 227 1:STN:280: DyaK1M%2Fjt12qsA%3D%3D 10.1159/000007984 9813406
30. JW Miller 2002 Homocysteine, folate deficiency, and Parkinson's disease Nutr Rev 60 410 413 10.1301/002966402320964089 12521146 (Pubitemid 36026501)
31. K Nakaso K Yasui H Kowa, et al. 2003 Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with l-DOPA, homocysteine, and MTHFR genotype J Neurol Sci 207 19 23 1:CAS:528:DC%2BD3sXhsVCltbw%3D 10.1016/S0022-510X(02)00353-2 12614926 (Pubitemid 36287098)
32. PE O'Suilleabhain T Bottiglieri RB Dewey Jr S Sharma R Diaz-Arrastia 2004 Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease Mov Disord 19 1403 1408 10.1002/mds.20253 15390053 (Pubitemid 40109481)
33. K Yasui H Kowa K Nakaso T Takeshima K Nakashima 2000 Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD Neurology 55 437 440 1:STN:280:DC%2BD3cvgs1GisQ%3D%3D 10932284
34. SE Daniel AJ Lees 1993 Disease Society Brain Bank, London: overview and research J Neural Transm Suppl 39 165 172 1:STN:280:DyaK3szmslCntg%3D%3D 8360656
35. H Refsum AD Smith PM Ueland, et al. 2004 Facts and recommendations about total homocysteine determinations: an expert opinion Clin Chem 50 1 3 32 1:CAS:528:DC%2BD2cXovFWhsA%3D%3D 10.1373/clinchem.2003.021634 14709635 (Pubitemid 38125696)
36. P Lamberti S Zoccolella E Armenise, et al. 2005 Hyperhomocysteinemia in l-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration Eur J Neurol 12 365 368 1:STN:280:DC%2BD2M7nt1OgsA%3D%3D 10.1111/j.1468-1331.2004.00973.x 15804266 (Pubitemid 40524176)
37. M Bareš P Kaňovský I Rektor 2002 Úloha inhibitorů katechol-O-metyl-transferázy (COMT) v léčbě pozdních komplikací Parkinsonovy nemoci-účinnost a bezpečnost entakaponu (Comtan®) Čes a Slov Neurol Neurochir 65 /98 69 75